16 research outputs found

    Ibuprofen Can Induce Syndrome of Inappropriate Diuresis in Healthy Young Patients

    Get PDF
    A 30-year-old caucasian woman, without past medical history or known drug use, was admitted to the emergency department for persistent fever and arthralgias. The laboratory analysis showed moderate hypoosmolar hyponatremia (Na: 132 mmol/L, osmolality: 239 mOsm/L), normal sodium excretion (<20 mmol/L), and a high urinary osmolality (415 mOsm/L). Later, she deteriorated with seizures and deeper hyponatremia (Na: 113 mmol/L) and so was moved to the critical care unit. At first, no obvious aetiology was found, the patient was euvolemic, as she was well hydrated and lacked concerning findings of heart failure, renal disease, or liver cirrhosis. A syndrome of inappropriate diuresis (SIAD) was proposed, and corrective measures were started immediately to reduce her hyponatremia, including restriction of fluid intake. The administration of intravenous hypertonic saline solution permitted normal neurological status to be restored and corrected the sodium concentration but induced reversible acute renal failure. Further investigation revealed that the patient had ingested 8 g ibuprofen two days before admission. After other aetiologies were ruled out, drug-induced SIAD due to ibuprofen was the most likely diagnosis for this patient. SIAD-associated hyponatremia and acute renal failure are rare side effects of nonsteroidal anti-inflammatory drugs, particularly in young people. Therefore, this case may represent a unique case of NSAID-induced SIAD and highlight the need to obtain thorough medication histories and exclude all other potential causes in hyponatremic patients

    Splenic infarction during Plasmodium ovale acute malaria: first case reported

    Get PDF
    The splenic complications of acute malaria include two different prognostic and treatment entities: splenic infarction and splenic rupture. This is the first case of splenic infarction during an acute malaria due to Plasmodium ovale in a 34-year-old man. As in the majority other described cases of splenic infarction, the course was spontaneously favourable, suggesting that this complication was relatively benign compared to splenic rupture, which is life-threatening and usually necessitating surgery

    Livrable L5.1 Choix des scénarios d&apos;interactions VL / 2RM - Projet SURCA - Sécurité des Usagers de la Route et Conduite Automatisée

    No full text
    Les questions posĂ©es par la cohabitation de vĂ©hicules de plus en plus automatisĂ©s avec des vĂ©hicules conventionnels et des usagers vulnĂ©rables, cyclistes, piĂ©tons, deux-roues motorisĂ©s, sont au coeur des prĂ©occupations des dĂ©cideurs publics, constructeurs, ou spĂ©cialistes de l&apos;infrastructure routiĂšre et de la sĂ©curitĂ© routiĂšre. Tous ont l&apos;espoir que ces nouvelles technologies contribuent Ă  amĂ©liorer la sĂ©curitĂ© routiĂšre. L&apos;objectif global du projet « SĂ©curitĂ© des Usagers de la Route et Conduite AutomatisĂ©es, SURCA » est de contribuer Ă  une meilleure intĂ©gration de la Conduite AutomatisĂ©e dans la circulation actuelle. Les partenaires du projet (Ifsttar, DSR, Ceesar, Cerema, Vedecom, Lab), ont ainsi comme objectif d&apos;identifier quelles interactions existent et quelles stratĂ©gies pertinentes sont mises en place par les conducteurs pour proposer des recommandations aux concepteurs de vĂ©hicules autonomes sur les besoins en termes d&apos;interactions et en termes de comportement du vĂ©hicule autonome. Pour cela, il est prĂ©vu d&apos;analyser des bases de donnĂ©es existantes sur la conduite des vĂ©hicules conventionnels et d&apos;identifier les facteurs qui peuvent expliquer des comportements diffĂ©rents. Les connaissances issues de ces bases seront utilisables pour simuler l&apos;introduction de la conduite automatisĂ©e de niveaux 3, 4 et 5, avec des taux de pĂ©nĂ©tration faibles. La gestion des interactions avec les autres usagers doit ĂȘtre rĂ©alisĂ©e dĂšs que le vĂ©hicule peut Ă©voluer en autonomie sans supervision du conducteur, quelles que soient la durĂ©e et les sections sur lesquelles cette automatisation sera possible. En cas de taux de pĂ©nĂ©tration trĂšs important, d&apos;autres types d&apos;interactions risquent de se mettre en place et devront alors ĂȘtre Ă©tudiĂ©s. Ce travail a permis d&apos;identifier les scĂ©narios d&apos;interaction critiques entre un futur VĂ©hicule AutomatisĂ© (VA) et un deux-roues motorisĂ©. A partir des scĂ©narios d&apos;accidents VL/2RM connus dans les bases de donnĂ©es VOIESUR et FLAM, une premiĂšre analyse « macro » a permis d&apos;identifier les scĂ©narios Ă  enjeu. Cette analyse repose sur l&apos;Ă©valuation de la criticitĂ© des interactions avec un potentiel vĂ©hicule automatisĂ© Ă  l&apos;aide de quatre critĂšres : Est-ce que le scĂ©nario est challengeant pour le VA, est-il frĂ©quemment rencontrĂ© lors de la conduite « normale », gĂ©nĂšre-t-il souvent une situation d&apos;incident et nĂ©cessite-t-il une intervention humaine dĂ©cisive pour Ă©viter l&apos;accident. Les grandes familles d&apos;interaction retenues pour le 2RM sont : Les situations en intersection et plus particuliĂšrement lorsque le VL souhaite effectuer une manoeuvre de tourne Ă  gauche. Les situations dans les giratoires mais plus particuliĂšrement les situations d&apos;insertion (du VL et du 2RM) et de sortie. Les changements de voie du VL alors qu&apos;un 2RM circule dĂ©jĂ  sur cette voie ou qu&apos;il est en train d&apos;effectuer une remontĂ©e de file. Les situations oĂč le 2RM est en phase de dĂ©passement du VL car il peut venir perturber son comportement. Les situations oĂč le VL exĂ©cute une insertion sur une voie principale alors qu&apos;un 2RM circule sur cette derniĂšre. Puis une deuxiĂšme analyse « micro » a permis de mieux cerner les paramĂštres Ă  prendre en compte dans ces scĂ©narios. Les partenaires du projet devaient prĂ©ciser les types d&apos;analyses qu&apos;ils souhaitaient rĂ©aliser Ă  partir du tableau des scĂ©narios retenus, en utilisant une fiche d&apos;analyse comportementale Ă©laborĂ©e par le WP3 pour dĂ©crire, au mieux, les situations qu&apos;ils souhaitaient rechercher dans les bases de donnĂ©es et les paramĂštres Ă  disposer pour mener ces analyses. Parmi les analyses qui seront rĂ©alisĂ©es, on trouve notamment des problĂ©matiques portant sur le comportement du 2RM et la rĂ©action du VA face Ă  ces comportements, la difficultĂ© pour le VA de choisir une manoeuvre Ă  rĂ©aliser, l&apos;anticipation d&apos;une manoeuvre d&apos;un 2RM, les normes comportementales des usagers de VL vis-Ă -vis des 2RM, la dynamique du 2RM, etc. De nombreuses questions de recherches concernent notamment les situations lorsque le 2RM effectue une manoeuvre de dĂ©passement, une remontĂ©e de file ou en intersection

    Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial

    No full text
    International audienceIbrutinib, obinutuzumab plus venetoclax demonstrate synergy in pre-clinical models of mantle-cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multi-center prospective phase I/II trial, aimed to determine the maximum tolerated dose (MTD) of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide-quantitative polymerase chain reaction (ASO-qPCR). Between Oct 14, 2015 to May 29, 2018, forty-eight patients were enrolled. No dose limiting toxicity (DLT) was reported, and venetoclax at 400mg per day was chosen for extension. Eighteen (75%) relapsed and 8 (53%) untreated patients experienced grade 3/4 adverse events (AEs). The complete response rate assessed by positron-emission tomography at the end of cycle 6 was 67% in relapsed and 86.6% in untreated patients. MRD clearance for evaluable patients was seen in 71.5% of relapsed (10 out of 14) and 100% of untreated MRD-evaluable patients (n=12), at the end of three cycles. The median follow-up (mFU) for relapsed patients was 17 months (range, 10 to 35). The 2-years PFS was 69.5% (95% CI, 52.9-91.4%) and 68.6% (95% CI, 49.5-95.1%) for OS. The mFU was 14 months (range, 5 to 19) for untreated patients, the 1-year PFS was 93.3% (95% CI, 81.5-100%). Obinutuzimab, ibrutinib and venetoclax combination is well tolerated and provides high response rates including at the molecular level in relapsed and untreated MCL patients

    High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure

    Get PDF
    BACKGROUND: Whether noninvasive ventilation should be administered in patients with acute hypoxemic respiratory failure is debated. Therapy with high-flow oxygen through a nasal cannula may offer an alternative in patients with hypoxemia. METHODS: We performed a multicenter, open-label trial in which we randomly assigned patients without hypercapnia who had acute hypoxemic respiratory failure and a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of 300 mm Hg or less to high-flow oxygen therapy, standard oxygen therapy delivered through a face mask, or noninvasive positive-pressure ventilation. The primary outcome was the proportion of patients intubated at day 28; secondary outcomes included all-cause mortality in the intensive care unit and at 90 days and the number of ventilator-free days at day 28. RESULTS: A total of 310 patients were included in the analyses. The intubation rate (primary outcome) was 38% (40 of 106 patients) in the high-flow-oxygen group, 47% (44 of 94) in the standard group, and 50% (55 of 110) in the noninvasive-ventilation group (P = 0.18 for all comparisons). The number of ventilator-free days at day 28 was significantly higher in the high-flow-oxygen group (24±8 days, vs. 22±10 in the standard-oxygen group and 19±12 in the noninvasive-ventilation group; P = 0.02 for all comparisons). The hazard ratio for death at 90 days was 2.01 (95% confidence interval [CI], 1.01 to 3.99) with standard oxygen versus high-flow oxygen (P = 0.046) and 2.50 (95% CI, 1.31 to 4.78) with noninvasive ventilation versus high-flow oxygen (P = 0.006). CONCLUSIONS: In patients with nonhypercapnic acute hypoxemic respiratory failure, treatment with high-flow oxygen, standard oxygen, or noninvasive ventilation did not result in significantly different intubation rates. There was a significant difference in favor of high-flow oxygen in 90-day mortality. (Funded by the Programme Hospitalier de Recherche Clinique Interrégional 2010 of the French Ministry of Health; FLORALI ClinicalTrials.gov number, NCT01320384.
    corecore